Global Tyrosine Kinase JAK Inhibitors Market Report By Type (Tofacitinib, Ruxolitinib, And Baricitinib), Applications (Rheumatoid Arthritis (RA), Polycythemia Vera (PCV), Myelofibrosis (MF), And Others) And By Regions - Industry Trends, Size, Share, Growth, Estimation and Forecast, 2018-2025
ID:VMR11211133
July 2019
Report Formats:

As per this study the Global Tyrosine Kinase JAK Inhibitors Market was valued USD XXX MN (by revenue) in 2018 and is anticipated to reach USD XXX MN by 2025 with a CAGR of X.X%. By volume, the market was estimated XXX KT in 2018 and is expected to reach XXX KT by 2025 with a CAGR of X.X%.
 
JAK inhibitors are also known as Janus kinase inhibitors are categorized under those enzymes which play a significant role in the synthesis of blood cells, promote cell growth and immune responses in the human body. There are basically four members in the JAK family which include JAK-1, 2, 3 and Tyrosine Kinase 2 (TYK2). Moreover, these inhibitors act as a therapeutic agent in the treatment of chronic disease like cancer and inflammatory because its prime function is to restrict the formation of lymphocytes.
 
Market Dynamics
 
The growth of the tyrosine kinase inhibitors can be attributed to the rising prevalence of cancer and autoimmune disease across the globe coupled with the expanding healthcare sector. Rising adoption of tyrosine kinase inhibitors for the treatment of cancer because of specificity and various benefits over radiotherapy and chemotherapy is further expected to favor market growth. Ongoing development of novel drugs for the treatment of cancer coupled with the rising investment in the healthcare and pharmaceutical industry by respective regulatory bodies is also projected to raise the market value over the forecast timeline.
 
This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter’s five forces analysis, market attractiveness analysis and value chain analysis. These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities. Additionally, these tools also provide a detailed analysis of each application/product segment in the global market of tyrosine kinase JAK inhibitors.
 
Market Segmentation
 
The broad tyrosine kinase JAK inhibitors market has been sub-grouped into type and application. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target specific market. This detail will lead to a focused approach leading to identification of better opportunities.
 
By Type

  • Tofacitinib
  • Ruxolitinib
  • Baricitinib
 
By Application
  • Rheumatoid Arthritis (RA)
  • Polycythemia Vera (PCV)
  • Myelofibrosis (MF)
  • Others
 
Regional Analysis
 
Furthermore, the report comprises of the geographical segmentation which mainly focuses on current and forecast demand for tyrosine kinase JAK inhibitors in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report further focuses on demand for individual application segments in all the regions.
 
Europe Tyrosine Kinase JAK Inhibitors Market By Revenue (USD MN)
 
Europe Tyrosine Kinase JAK Inhibitors Market By Revenue
 
The report also covers detailed competitive landscape including company profiles of key players operating in the global market. The key players in the tyrosine kinase JAK inhibitors market includes AbbVie, Astellas Pharma, Celgene, CTI BioPharma, Eli Lilly, Galapagos, Gilead, Incyte, Novartis, Pfizer, Sanofi, Teva, Vertex, and others. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.
 
 
METHODOLOGY:
 
A combination of primary and secondary research has been used to determine the market estimates and forecasts. Sources used for secondary research include (but not limited to) Paid Data Sources, Company Websites, Technical Journals, Annual Reports, SEC Filings and various other industry publications. Specific details on methodology used for this report can be provided on demand.

1. INTRODUCTION

  • Introduction To Tyrosine kinase JAK inhibitors
  • Report Description
    • Objectives Of The Study
    • Assumptions
  • Research Scope
  • Research Methodology
    • Data Source
 
2. EXECUTIVE SUMMARY
  • Market Highlight
  • Global Tyrosine kinase JAK inhibitors Market: Snapshot
 
3. MARKET ANALYSIS
  • Drivers
  • Restraints
  • Opportunities
  • Porter’s Five Forces Analysis
  • Value Chain Analysis
 
4. TYROSINE KINASE JAK INHIBITORS MARKET ANALYSIS BY TYPE
  • Market In Tofacitinib
  • Market In Ruxolitinib
  • Market In Baricitinib
 
5. TYROSINE KINASE JAK INHIBITORS MARKET ANALYSIS BY APPLICATION
  • Market In Rheumatoid Arthritis (RA)
  • Market In Polycythemia Vera (PCV)
  • Market In Myelofibrosis (MF)
  • Market In Others
 
6. TYROSINE KINASE JAK INHIBITORS MARKET ANALYSIS BY GEOGRAPHY
  • North America (NA)
    • North America Market Estimates
    • North America Market Estimates By Country
    • United States (U.S.) Market Estimates By Segments
    • Rest Of North America Market Estimates By Segments
  • Europe (EU)
    • Europe Market Estimates
    • Europe Market Estimates By Country
    • United Kingdom (UK) Market Estimates By Segments
    • Germany Market Estimates By Segments
    • France Market Estimates By Segments
    • Rest Of Europe Market Estimates By Segments
  • Asia Pacific (APAC)
    • Asia Pacific Market Estimates
    • Asia Pacific Market Estimates By Country  
    • China Market Estimates By Segments
    • Japan Market Estimates By Segments
    • India Market Estimates By Segments
    • Rest Of Asia Pacific Market Estimates By Segments  
  • Latin America (LA)   
    • Latin America Market Estimates
    • Latin America Market Estimates By Country
    • Brazil Market Estimates By Segments
    • Rest Of Latin America Market Estimates By Segments
  • Middle East And Africa (MEA)   
    • Middle East And Africa Market Estimates
    • Middle East And Africa Market Estimates By Country
    • Middle East Market Estimates By Segments
    • Africa Market Estimates By Segments
 
7. COMPETITIVE LANDSCAPE OF THE TYROSINE KINASE JAK INHIBITORS COMPANIES
  • Market Competition
  • Partnerships/Collaborations/Agreements
  • Mergers And Acquisitions
  • New Product Launches
  • Other Developments
 
8. COMPANY PROFILES OF THE TYROSINE KINASE JAK INHIBITORS INDUSTRY (Company Overview, Financial, Major Products & Recent Development)
  • AbbVie
  • Astellas Pharma
  • Celgene
  • CTI BioPharma
  • Eli Lilly
  • Galapagos
  • Gilead
  • Incyte
  • Novartis
  • Pfizer
  • Sanofi
  • Teva
  • Vertex
  • Others
 
* Tentative TOC
 
LIST OF TABLES
 
Table 1.  Market Highlights Of Tyrosine Kinase JAK Inhibitors
Table 2.  Global Tyrosine Kinase JAK Inhibitors Market By Types
Table 3.  Global Tyrosine Kinase JAK Inhibitors Market By Application
Table 4.  Global Tyrosine Kinase JAK Inhibitors Market By Geography
Table 5.  North America Tyrosine Kinase JAK Inhibitors Market
Table 6.  Europe Tyrosine Kinase JAK Inhibitors Market
Table 7.  Asia Pacific Tyrosine Kinase JAK Inhibitors Market
Table 8.  Latin America Tyrosine Kinase JAK Inhibitors Market
Table 9.  Middle East And Africa Tyrosine Kinase JAK Inhibitors Market 
Table 10. Partnership/Collaboration/Agreements
Table 11. Mergers And Acquisitions
Table 12. New Product Development
Table 13. Other Developments
  
LIST OF FIGURES
 
Fig. 1.     Market Segmentation Of Tyrosine Kinase JAK Inhibitors Market 
Fig. 2.     Top-Down Approach   
Fig. 3.     Bottom-Up Approach   
Fig. 4.     Market Highlights Of Tyrosine Kinase JAK Inhibitors
Fig. 5.     Porter’s Five Forces Analysis
Fig. 6.     Value Chain Analysis
Fig. 7.     Global Tyrosine Kinase JAK Inhibitors Market By Types
Fig. 8.     Global Tyrosine Kinase JAK Inhibitors Market By Application
Fig. 9.     Global Tyrosine Kinase JAK Inhibitors Market By Geography
Fig. 10.   North America Tyrosine Kinase JAK Inhibitors Market
Fig. 11.   Europe Tyrosine Kinase JAK Inhibitors Market
Fig. 12.   Asia Pacific Tyrosine Kinase JAK Inhibitors Market
Fig. 13.   Latin America Tyrosine Kinase JAK Inhibitors Market
Fig. 14.   Middle East And Africa Tyrosine Kinase JAK Inhibitors Market
Fig. 15.   Market Share Of Tyrosine Kinase JAK Inhibitors Companies
Fig. 16.   Recent Developments In Tyrosine Kinase JAK Inhibitors Industry
 
 
* Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

Objectives of Study

  • Define and measure the global market
  • Volume or revenue forecast of the global market and its various sub-segments with respect to main geographies
  • Analyze and identify major market trends along with the factors driving or inhibiting the market growth
  • Study the company profiles of the major market players with their market share
  • Analyze competitive developments

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

Client First Policy
Excellent Quality
Robust After Sales Support
24/7 Email Support

Clients

Testimonials